Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:100:117-122.
doi: 10.1016/j.ijid.2020.08.012. Epub 2020 Aug 7.

New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France

Affiliations

New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France

Timothée Klopfenstein et al. Int J Infect Dis. 2020 Nov.

Abstract

Background: New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.

Methods: We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comté Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases.

Results: Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(±2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (±5, [1-21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0-8.6] vs 5.3 [2.1-8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths.

Conclusions: Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.

Keywords: Anosmia; Clinical features; Coronavirus disease 2019; Dysgeusia; Symptoms.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests. We thank all patients involved in the study.

Similar articles

Cited by

References

    1. Akerlund A., Bende M., Murphy C. Olfactory threshold and nasal mucosal changes in experimentally induced common cold. Acta Otolaryngol (Stockh). 1995;115(January (1)):88–92. - PubMed
    1. Alobid I., Cardelus S., Benítez P., Guilemany J.M., Roca-Ferrer J., Picado C. Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. Rhinology. 2011;49(December (5)):519–524. - PubMed
    1. Anon The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. 2017. https://www.ncbi.nlm.nih.gov/pubmed/?term=The+neuroinvasive+potential+of... [cited 2020 Apr 17]. Available from: - PMC - PubMed
    1. Bernard Stoecklin S., Rolland P., Silue Y., Mailles A., Campese C., Simondon A. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2020;25(6) - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(February (10223)):507–513. - PMC - PubMed